Facilitated cascade testing (FaCT): a randomized controlled trialRoni Nitecki, Haley A Moss, Catherine H Watson, Diana L Urbauer, Alexander Melamed, Karen H Lu, Steven M Lipkin, Kenneth Offit, Jose Alejandro Rauh-Hain, Melissa K Frey
18 December 2020
A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese Gynecologic Oncology Group study (JGOG1082)Akiko Furusawa, Munetaka Takekuma, Keita Mori, Tomoka Usami, Eiji Kondo, Shin Nishio, Koji Nishino, Yuichiro Miyamoto, Ryoichi Yoshimura, Miho Watanabe, Mikio Mikami, Takayuki Enomoto
4 March 2021
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA TrialAntonio Gonzalez Martin, Luisa Sanchez Lorenzo, Nicoletta Colombo, René dePont Christensen, Florian Heitz, Mihai Meirovitz, Frederic Selle, Toon van Gorp, Nuria Alvarez, Javier Sanchez, Carmen Marqués
14 December 2020
Diagnostic performance of ultrasound in assessing the extension of the disease in patients with suspicion of malignant ovarian tumor: correlation between ultrasound parameters and Fagotti’s scoreMaria Cristina Moruzzi, Giulia Bolomini, Francesca Moro, Floriana Mascilini, Silvia Ficarelli, Giuliana Beneduce, Maria Teresa Giudice, Tina Pasciuto, Rossana Moroni, Giovanni Scambia, Anna Fagotti, Antonia Carla Testa
7 September 2020
Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trialFaiza Gaba, Sadiyah Robbani, Naveena Singh, W Glenn McCluggage, Nafisa Wilkinson, Raji Ganesan, Gareth Bryson, Gareth Rowlands, Charlotte Tyson, Rupali Arora, Ertan Saridogan, Helen Hanson, Matthew Burnell, Rosa Legood, D Gareth EvansSee the full list of authors
8 September 2020
Neoadjuvant chemotherapy followed by radical surgery versus concurrent chemoradiotherapy in patients with FIGO stage IIB cervical cancer: the CSEM 006 studyHua Tu, He Huang, Yi Ouyang, Qing Liu, Bingna Xian, Kun Song, Gang Chen, Yuanming Shen, Jihong Liu
9 June 2020
ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapyOsnat Elyashiv, Jonathan Ledermann, Gita Parmar, Laura Farrelly, Nicholas Counsell, Amanda Feeney, Fatima El-Khouly, Ian Macdonald, Andreia Neto, Esther Arthur-Darkwa, Eva Burnett, Gordon C Jayson, Linda Mileshkin, Charlie Gourley, Shibani Nicum
23 October 2020
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)Philipp Harter, Patricia Pautier, Els Van Nieuwenhuysen, Alexander Reuss, Andres Redondo, Kristina Lindemann, Christian Kurzeder, Edgar Petru, Florian Heitz, Jalid Sehouli, Nikolaus Degregorio, Pauline Wimberger, Alexander Burges, Nadin Cron, Jonathan LedermannSee the full list of authors
30 June 2020
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancerAnne Sophie V M van den Heerik, Nanda Horeweg, Remi A Nout, Ludy C H W Lutgens, Elzbieta M van der Steen-Banasik, G Henrike Westerveld, Hetty A van den Berg, Annerie Slot, Friederike L A Koppe, Stefan Kommoss, Jan Willem M Mens, Marlies E Nowee, Stefan Bijmolt, David Cibula, Tanja C StamSee the full list of authors
12 October 2020
Sentinel lymph node biopsy versus pelvic lymphadenectomy in early-stage cervical cancer: a multi-center randomized trial (PHENIX/CSEM 010)Hua Tu, He Huang, Bingna Xian, Jibin Li, Ping Wang, Weidong Zhao, Xiaojun Chen, Xing Xie, Chunyan Wang, Beihua Kong, Jing Xiao, Ping Zhang, Jihong Liu,
24 September 2020